GnRH for Infertility

University Reproductive Associates, Hasbrouck Heights, NJ
GnRH +1 morePhase 4RecruitingLed by Peter G McGovern, MDResearch Sponsored by University Reproductive Associates

Study Summary

This trial found that using a GnRH agonist in addition to progesterone during IVF cycles improves implantation and live birth rates.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Live birth per transfer
Secondary outcome measures
clinical pregnancy
implantation rates
rates of OHSS

Side effects data

From 2009 Phase 2 trial • 36 Patients • NCT00586898
Hot Flashes
Cardiovascular, other
Study treatment Arm
All Participants

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GnRH agonistExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Find a site

Who is running the clinical trial?

University Reproductive AssociatesLead Sponsor
5 Previous Clinical Trials
109 Total Patients Enrolled
3 Trials studying Infertility
99 Patients Enrolled for Infertility
Peter G McGovern, MDPrincipal Investigator
Rutgers University

Media Library

GnRH Clinical Trial Eligibility Overview. Trial Name: NCT02357654 — Phase 4
Infertility Research Study Groups: GnRH agonist, Placebo
Infertility Clinical Trial 2023: GnRH Highlights & Side Effects. Trial Name: NCT02357654 — Phase 4
GnRH 2023 Treatment Timeline for Medical Study. Trial Name: NCT02357654 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are currently participating in this clinical experiment?

"Affirmative. According to the figures on, this research effort is actively trying to gather 350 participants from a single site. The trial was first listed 11/1/2015 and most recently updated 5/25/2022."

Answered by AI

To what extent is GnRH a safe and viable therapeutic option?

"There is overwhelming evidence in favor of GnRH's safety, so it earned a score of 3."

Answered by AI

Is this trial currently seeking participants?

"According to, this particular medical trial is in need of participants at the present time. This study was first made available on November 1st 2015 and has undergone its most recent update on May 25th 2022."

Answered by AI

Who makes a suitable candidate for participating in this medical experiment?

"This trial aims to recruit 350 people between 18 and 40 who are struggling with infertility. To be considered, patients must meet these criteria."

Answered by AI

What other research has been done on GnRH's efficacy in a clinical setting?

"Currently, there are 46 active GnRH-related clinical trials with 10 in their third phase. The majority of the studies for this hormone can be found at sites in Chicago, Illinois; however, across the entire US there is a total of 1321 trial centres conducting research."

Answered by AI

Does the age bracket for this research include individuals over 40?

"This medical trial is only available to applicants aged between 18-40. Patients younger than 18 have 19 separate studies they can participate in, while those over 65 may join 59 different trials."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
New York
How old are they?
18 - 65
What site did they apply to?
University Reproductive Associates
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Most responsive sites:
  1. University Reproductive Associates: < 48 hours
Average response time
  • < 2 Days
~53 spots leftby Mar 2025